The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Bumsang Shim - One of the best experts on this subject based on the ideXlab platform.

  • significance of serum ferritin as a prognostic factor in advanced Hepatobiliary Cancer patients treated with korean medicine a retrospective cohort study
    BMC Complementary and Alternative Medicine, 2018
    Co-Authors: Anna Song, Wankyu Eo, Bumsang Shim
    Abstract:

    Advanced Hepatobiliary Cancers are highly lethal Cancers that require precise prediction in clinical practice. Serum ferritin level increases in malignancy and high serum ferritin level is associated with poor survival in various Cancers. This study aimed to identify whether serum ferritin could independently predict the overall survival (OS) of patients with advanced Hepatobiliary Cancers. The retrospective cohort study was performed by reviewing medical records of patients with advanced Hepatobiliary Cancers from June 2006 to September 2016. The demographic and clinicopathological characteristics as well as the biochemical markers were evaluated at the initiation of Korean medicine (KM) treatment. The OS was calculated using Kaplan-Meier estimates. The Cox proportional hazard model was used to identify the independent prognostic significance of serum ferritin for survival. The median OS of all subjects was 5.1 months (range, 0.5–114.9 months). The median OS of group with low ferritin levels and that with high ferritin levels was 7.5 months (range, 0.7–114.9 months) and 2.8 months (range, 0.5–22.8 months), respectively (P < 0.001). The results of the univariate analysis showed that the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P = 0.002), tumor type (P = 0.001), prior treatment (P = 0.023), serum ferritin (P < 0.001), hemoglobin (P = 0.002), total bilirubin (P = 0.002), gamma-glutamyl transpeptidase (P = 0.007), albumin (P = 0.013), white blood cell (P = 0.002), and C-reactive protein (CRP) (P < 0.001) were significant factors for the patients’ survival outcome. On multivariate analysis controlling confounding factors, ferritin (P = 0.041), CRP (P = 0.010), ECOG-PS (P = 0.010), and tumor type (P = 0.018) were identified as independent prognostic factors for survival. These results indicate that serum ferritin is a valid clinical biochemical marker to predict survival of patients with advanced Hepatobiliary Cancers.

  • Significance of serum ferritin as a prognostic factor in advanced Hepatobiliary Cancer patients treated with Korean medicine: a retrospective cohort study
    BMC Complementary and Alternative Medicine, 2018
    Co-Authors: Anna Song, Wankyu Eo, Bumsang Shim
    Abstract:

    Advanced Hepatobiliary Cancers are highly lethal Cancers that require precise prediction in clinical practice. Serum ferritin level increases in malignancy and high serum ferritin level is associated with poor survival in various Cancers. This study aimed to identify whether serum ferritin could independently predict the overall survival (OS) of patients with advanced Hepatobiliary Cancers. The retrospective cohort study was performed by reviewing medical records of patients with advanced Hepatobiliary Cancers from June 2006 to September 2016. The demographic and clinicopathological characteristics as well as the biochemical markers were evaluated at the initiation of Korean medicine (KM) treatment. The OS was calculated using Kaplan-Meier estimates. The Cox proportional hazard model was used to identify the independent prognostic significance of serum ferritin for survival. The median OS of all subjects was 5.1 months (range, 0.5–114.9 months). The median OS of group with low ferritin levels and that with high ferritin levels was 7.5 months (range, 0.7–114.9 months) and 2.8 months (range, 0.5–22.8 months), respectively (P 

Katherine A Mcglynn - One of the best experts on this subject based on the ideXlab platform.

  • Seropositivity for Helicobacter pylori and Hepatobiliary Cancers in the PLCO study.
    British Journal of Cancer, 2020
    Co-Authors: Rishi Makkar, Neal D Freedman, Katherine A Mcglynn, Julia Butt, Wen-yi Huang, Jill Koshiol, Michael Pawlita, Tim Waterboer, Gwen Murphy
    Abstract:

    Helicobacter has been suggested to play a possible role in hepatitis, gallstones, and Hepatobiliary tumours. We assessed whether seropositivity to 15 H. pylori proteins was associated with subsequent incidence of 74 biliary tract and 105 liver Cancer cases vs. 357 matched controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Odds ratios and 95% confidence intervals were computed by conditional logistic regression after adjustment for known Hepatobiliary Cancer risk factors. H. pylori seropositivity was not associated with either biliary tract (1.76, 0.90–3.46) or liver Cancer (0.87, 0.46–1.65). CagA seropositivity was associated with both endpoints, although the latter association was not statistically significant (biliary tract: 2.16, 1.03–4.50; liver Cancer: 1.96, 0.98–3.93) and neither association was statistically significant after correcting for multiple comparisons. Together, these results suggest possible associations between H. pylori and Hepatobiliary Cancer and suggest the value of future studies investigating the association. Trial registration number: NCT00339495.

  • associations between autoimmune conditions and Hepatobiliary Cancer risk among elderly us adults
    International Journal of Cancer, 2019
    Co-Authors: Emma E Mcgee, Felipe A Castro, Eric A Engels, Neal D Freedman, Ruth M Pfeiffer, Leticia Nogueira, Rachael Z Stolzenbergsolomon, Katherine A Mcglynn, Kari Hemminki
    Abstract:

    Growing evidence suggests that people with autoimmune conditions may be at increased risk of Hepatobiliary tumors. In the present study, we evaluated associations between autoimmune conditions and Hepatobiliary Cancers among adults aged ≥66 in the United States. We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data (1992–2013) to conduct a population-based, case–control study. Cases (n = 32,443) had primary Hepatobiliary Cancer. Controls (n = 200,000) were randomly selected, Cancer-free adults frequency-matched to cases by sex, age and year of selection. Using multivariable logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) for associations with 39 autoimmune conditions identified via Medicare claims. We also conducted separate analyses for diagnoses obtained via inpatient versus outpatient claims. Sixteen conditions were associated with at least one Hepatobiliary Cancer. The strongest risk estimates were for primary biliary cholangitis with hepatocellular carcinoma (OR: 31.33 [95% CI: 23.63–41.56]) and primary sclerosing cholangitis with intrahepatic cholangiocarcinoma (7.53 [5.73–10.57]), extrahepatic cholangiocarcinoma (5.59 [4.03–7.75]), gallbladder Cancer (2.06 [1.27–3.33]) and ampulla of Vater Cancer (6.29 [4.29–9.22]). Associations with Hepatobiliary-related conditions as a group were observed across nearly all Cancer sites (ORs ranging from 4.53 [95% CI: 3.30–6.21] for extrahepatic cholangiocarcinoma to 7.18 [5.94–8.67] for hepatocellular carcinoma). Restricting to autoimmune conditions diagnosed via inpatient claims, 6 conditions remained associated with at least one Hepatobiliary Cancer, and several risk estimates increased. In the outpatient restricted analysis, 12 conditions remained associated. Multiple autoimmune conditions are associated with Hepatobiliary Cancer risk in the US Medicare population, supporting a shared immuno-inflammatory etiology to these Cancers.

  • association of seropositivity to helicobacter species and biliary tract Cancer in the atbc study
    Hepatology, 2014
    Co-Authors: Gwen Murphy, Julia Butt, Angelika Michel, Philip R Taylor, Demetrius Albanes, Stephanie J Weinstein, Jarmo Virtamo, Dominick Parisi, Kirk Snyder, Katherine A Mcglynn
    Abstract:

    Helicobacter have been detected in human bile and Hepatobiliary tissue. Despite evidence that Helicobacter species promote gallstone formation and Hepatobiliary tumors in laboratory studies, it remains unclear whether Helicobacter species contribute to these Cancers in humans. We used a multiplex panel to assess whether seropositivity to 15 Helicobacter pylori proteins was associated with subsequent incidence of Hepatobiliary Cancers in the Finnish Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. We included 64 biliary Cancers, 122 liver Cancers, and 224 age-matched controls which occurred over the course of 22 years. Helicobacter pylori seropositivity was defined as those positive to ≥4 antigens. Odds ratios (OR) and 95% confidence intervals were adjusted for major Hepatobiliary Cancer risk factors. Among the controls, 88% were seropositive to H. pylori at baseline. Among those who subsequently developed Hepatobiliary Cancer, the prevalence of seropositivity was higher: 100% for gallbladder Cancer, 97% of extrahepatic bile duct Cancer, 91% of ampula of Vater Cancer, 96% of intrahepatic bile duct Cancer, and 94% of hepatocellular carcinoma. Although the OR for gallbladder Cancer could not be calculated, the OR for the other sites were 7.01 (95% confidence interval [CI]: 0.79-62.33), 2.21 (0.19-25.52), 10.67 (0.76-150.08), and 1.20 (0.42-3.45), respectively, with an OR of 5.47 (95% CI: 1.17-25.65) observed for the biliary tract Cancers combined. ORs above 1 were observed for many of the investigated antigens, although most of these associations were not statistically significant. Conclusion: Seropositivity to H. pylori proteins was associated with an increased risk of biliary tract Cancers in ATBC. Further studies are needed to confirm our findings and to determine how H. pylori might influence the risk of biliary tract Cancer. (Hepatology 2014;60:1962–1970)

  • risk of Hepatobiliary Cancer after solid organ transplant in the united states
    Clinical Gastroenterology and Hepatology, 2014
    Co-Authors: Jill Koshiol, Katherine A Mcglynn, Karen Pawlish, Marc T Goodman, Eric A Engels
    Abstract:

    Background & Aims Studies of liver Cancer risk in recipients of solid organ transplants generally have been small, yielding mixed results, and little is known about biliary tract Cancers among transplant recipients. Methods We identified incident Hepatobiliary Cancers among 201,549 US recipients of solid organs, from 1987 through 2008, by linking data from the US transplant registry with 15 Cancer registries. We calculated standardized incidence ratios (SIRs), comparing risk relative to the general population. We also calculated incidence rate ratios (RRs), comparing risk for hepatocellular carcinoma (HCC) and total (intrahepatic and extrahepatic) cholangiocarcinoma among subgroups of recipients. Results Of transplant recipients, 165 developed Hepatobiliary Cancers (SIR, 1.2; 95% confidence interval [CI], 1.0–1.4). HCC risk was increased among liver recipients (SIR, 1.5; 95% CI, 1.0–2.2), especially 5 or more years after transplant (SIR, 1.8; 95% CI, 1.0–3.0). Cholangiocarcinoma was increased among liver (SIR, 2.9; 95% CI, 1.6–4.8) and kidney recipients (SIR, 2.1; 95% CI, 1.3–3.1). HCC was associated with hepatitis B virus (RR, 3.2; 95% CI, 1.3–6.9), hepatitis C virus (RR, 10; 95% CI, 5.9–16.9), and non–insulin-dependent diabetes (RR, 2.5; 95% CI, 1.2–4.8). Cholangiocarcinoma was associated with azathioprine maintenance therapy (RR, 2.0; 95% CI, 1.1–3.7). Among liver recipients, primary sclerosing cholangitis was associated with an increased risk of cholangiocarcinoma, compared with the general population (SIR, 21; 95% CI, 8.2–42) and compared with liver recipients without primary sclerosing cholangitis (RR, 12.3; 95% CI, 4.1–36.4). Conclusions Risks for liver and biliary tract Cancer are increased among organ transplant recipients. Risk factors for these Cancers include medical conditions and potentially medications taken by recipients.

  • The association between frequency of vigorous physical activity and Hepatobiliary Cancers in the NIH-AARP Diet and Health Study.
    European Journal of Epidemiology, 2013
    Co-Authors: Gundula Behrens, Neal D Freedman, Katherine A Mcglynn, Charles E. Matthews, Steven C. Moore, James E. Everhart, Albert R. Hollenbeck, Michael F. Leitzmann
    Abstract:

    Despite a potential preventive effect of physical activity on Hepatobiliary Cancer, little information is available on the relation between the two. We studied the association between frequency of vigorous physical activity and Hepatobiliary Cancer among 507,897 participants of the NIH-AARP Diet and Health Study, aged 50–71 years at baseline in 1995/1996. During 10 years of follow-up, 628 incident cases of liver Cancer and 317 cases of extrahepatic biliary tract Cancer were registered. Physical activity levels were assigned according to the frequency of engagement in 20 min or more of vigorous physical activity per week: never/rarely (lowest level), less than once per week, 1–2 times per week, 3–4 times per week, 5 or more times per week (highest level). Using Cox regression, multivariate-adjusted relative risks (RR) comparing the highest with the lowest level of physical activity revealed a statistically significant decreased risk for liver Cancer (RR = 0.64, 95 % confidence interval (CI) = 0.49–0.84, p-trend

Anthony R Hayward - One of the best experts on this subject based on the ideXlab platform.

Nele Brusselaers - One of the best experts on this subject based on the ideXlab platform.

  • abstract 5049 associations of aspirin non aspirin nsaids statins and metformin with risk of biliary tract Cancer a swedish population based cohort study
    Cancer Research, 2019
    Co-Authors: Lorena Marcanobonilla, Mitesh J. Borad, Cathy D Schleck, Scott W Harmsen, Omid Sadrazodi, Tushar C Patel, Gloria M Petersen, Terry M Therneau, Lewis Rowland Roberts, Nele Brusselaers
    Abstract:

    Objectives: Biliary tract Cancers (BTCs) comprise the second most common type of Hepatobiliary Cancer. Given the increase in global BTC incidence, with associated morbidity and mortality, together with the limited therapeutic options, there is increasing interest in strategies for disease prevention. We performed a population-based cohort study to determine the association between low dose aspirin, non-aspirin NSAIDs, statins, metformin, other risk factors and the risk of biliary tract Cancer (BTC), while assessing confounding by sex. Methods: We conducted a nationwide Swedish population-based cohort study using the Swedish Prescribed Drug Registry, which virtually completely enumerates use of prescribed medications nationwide since 2005. BTC diagnosis (intrahepatic cholangiocarcinoma [iCCA], extrahepatic cholangiocarcinoma [eCCA] or gallbladder Cancer [GBC]) was ascertained from the Swedish Cancer Registry. Age-scaled Cox models, with exposure as time-varying covariates, were used to calculate hazard ratios (HRs), separately for men and women. Results: In the 5.7 million person cohort, the risk of iCCA was significantly lower in men using statins (HR 0.62,95%CI 0.39-1.00,p=0.05), with a non-significant reduction in women. Statin use was associated with a significantly decreased risk of eCCA in both women (HR 0.60,0.38-0.94,p=0.03) and men (HR 0.47,0.28-0.80,p=0.01). Low dose aspirin (HR 0.76,0.60-0.97,p=0.03) was associated with a lower risk of GBC only in women, while statins (HR 0.72,0.55-0.93,p=0.01) showed a significantly decreased risk of GBC in women and a non-significant reduction in men. For all BTC subtypes, combined use of low dose aspirin and statins did not confer additional risk reductions beyond those achieved by statins alone. Male and female users of non-aspirin NSAIDs appeared to be at increased risk of BTC and its subtypes. Metformin did not significantly affect risk of BTC. Conclusion: We performed the largest population-based cohort study evaluating risk and protective factors for BTC. Our results provide strong evidence in favor of the chemopreventive roles of low dose aspirin and statins in a subtype-and sex-specific manner. Individual risk factors contribute to development of BTC subtypes in different magnitudes. If randomized controlled clinical trials validate our findings and provide favorable evidence of the efficacy and safety of these drugs in the prevention of BTCs, our results could potentially be practice-changing, leading to improvements in the outcomes in this population. Citation Format: Lorena Marcano-Bonilla, Cathy D. Schleck, W. Scott Harmsen, Omid Sadr-Azodi, Mitesh J. Borad, Tushar Patel, Gloria M. Petersen, Terry M. Therneau, Lewis R. Roberts, Nele Brusselaers. Associations of aspirin, non-aspirin NSAIDs, statins, and metformin with risk of biliary tract Cancer: A Swedish population-based cohort study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5049.

Anna Song - One of the best experts on this subject based on the ideXlab platform.

  • significance of serum ferritin as a prognostic factor in advanced Hepatobiliary Cancer patients treated with korean medicine a retrospective cohort study
    BMC Complementary and Alternative Medicine, 2018
    Co-Authors: Anna Song, Wankyu Eo, Bumsang Shim
    Abstract:

    Advanced Hepatobiliary Cancers are highly lethal Cancers that require precise prediction in clinical practice. Serum ferritin level increases in malignancy and high serum ferritin level is associated with poor survival in various Cancers. This study aimed to identify whether serum ferritin could independently predict the overall survival (OS) of patients with advanced Hepatobiliary Cancers. The retrospective cohort study was performed by reviewing medical records of patients with advanced Hepatobiliary Cancers from June 2006 to September 2016. The demographic and clinicopathological characteristics as well as the biochemical markers were evaluated at the initiation of Korean medicine (KM) treatment. The OS was calculated using Kaplan-Meier estimates. The Cox proportional hazard model was used to identify the independent prognostic significance of serum ferritin for survival. The median OS of all subjects was 5.1 months (range, 0.5–114.9 months). The median OS of group with low ferritin levels and that with high ferritin levels was 7.5 months (range, 0.7–114.9 months) and 2.8 months (range, 0.5–22.8 months), respectively (P < 0.001). The results of the univariate analysis showed that the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P = 0.002), tumor type (P = 0.001), prior treatment (P = 0.023), serum ferritin (P < 0.001), hemoglobin (P = 0.002), total bilirubin (P = 0.002), gamma-glutamyl transpeptidase (P = 0.007), albumin (P = 0.013), white blood cell (P = 0.002), and C-reactive protein (CRP) (P < 0.001) were significant factors for the patients’ survival outcome. On multivariate analysis controlling confounding factors, ferritin (P = 0.041), CRP (P = 0.010), ECOG-PS (P = 0.010), and tumor type (P = 0.018) were identified as independent prognostic factors for survival. These results indicate that serum ferritin is a valid clinical biochemical marker to predict survival of patients with advanced Hepatobiliary Cancers.

  • Significance of serum ferritin as a prognostic factor in advanced Hepatobiliary Cancer patients treated with Korean medicine: a retrospective cohort study
    BMC Complementary and Alternative Medicine, 2018
    Co-Authors: Anna Song, Wankyu Eo, Bumsang Shim
    Abstract:

    Advanced Hepatobiliary Cancers are highly lethal Cancers that require precise prediction in clinical practice. Serum ferritin level increases in malignancy and high serum ferritin level is associated with poor survival in various Cancers. This study aimed to identify whether serum ferritin could independently predict the overall survival (OS) of patients with advanced Hepatobiliary Cancers. The retrospective cohort study was performed by reviewing medical records of patients with advanced Hepatobiliary Cancers from June 2006 to September 2016. The demographic and clinicopathological characteristics as well as the biochemical markers were evaluated at the initiation of Korean medicine (KM) treatment. The OS was calculated using Kaplan-Meier estimates. The Cox proportional hazard model was used to identify the independent prognostic significance of serum ferritin for survival. The median OS of all subjects was 5.1 months (range, 0.5–114.9 months). The median OS of group with low ferritin levels and that with high ferritin levels was 7.5 months (range, 0.7–114.9 months) and 2.8 months (range, 0.5–22.8 months), respectively (P